CN116585455A - 一种预防老年骨质疏松的营养包制剂及其应用 - Google Patents
一种预防老年骨质疏松的营养包制剂及其应用 Download PDFInfo
- Publication number
- CN116585455A CN116585455A CN202310596136.2A CN202310596136A CN116585455A CN 116585455 A CN116585455 A CN 116585455A CN 202310596136 A CN202310596136 A CN 202310596136A CN 116585455 A CN116585455 A CN 116585455A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- group
- calcium
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 18
- 206010039984 Senile osteoporosis Diseases 0.000 title claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 59
- 230000035764 nutrition Effects 0.000 claims abstract description 36
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 28
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 28
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 28
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 25
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 25
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 25
- 229940088594 vitamin Drugs 0.000 claims abstract description 25
- 229930003231 vitamin Natural products 0.000 claims abstract description 25
- 235000013343 vitamin Nutrition 0.000 claims abstract description 25
- 239000011782 vitamin Substances 0.000 claims abstract description 25
- 235000013336 milk Nutrition 0.000 claims abstract description 21
- 239000008267 milk Substances 0.000 claims abstract description 21
- 210000004080 milk Anatomy 0.000 claims abstract description 21
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 18
- 239000011707 mineral Substances 0.000 claims abstract description 18
- 241000233866 Fungi Species 0.000 claims abstract description 17
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 16
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 16
- -1 compound vitamin Chemical class 0.000 claims abstract description 16
- 239000003623 enhancer Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 16
- 235000021119 whey protein Nutrition 0.000 claims abstract description 16
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 15
- 235000021277 colostrum Nutrition 0.000 claims abstract description 14
- 210000003022 colostrum Anatomy 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 7
- 240000002624 Mespilus germanica Species 0.000 claims abstract 6
- 235000010755 mineral Nutrition 0.000 claims description 17
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000010008 shearing Methods 0.000 claims description 12
- 238000001694 spray drying Methods 0.000 claims description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 235000015872 dietary supplement Nutrition 0.000 claims description 8
- 229930003316 Vitamin D Natural products 0.000 claims description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
- 235000019166 vitamin D Nutrition 0.000 claims description 6
- 239000011710 vitamin D Substances 0.000 claims description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 6
- 229940046008 vitamin d Drugs 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 239000011790 ferrous sulphate Substances 0.000 claims description 5
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 5
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 5
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 5
- 229960002261 magnesium phosphate Drugs 0.000 claims description 5
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 5
- 239000004137 magnesium phosphate Substances 0.000 claims description 5
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 5
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 239000011746 zinc citrate Substances 0.000 claims description 5
- 235000006076 zinc citrate Nutrition 0.000 claims description 5
- 229940068475 zinc citrate Drugs 0.000 claims description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 5
- 229960001763 zinc sulfate Drugs 0.000 claims description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000009928 pasteurization Methods 0.000 claims description 2
- 229940098458 powder spray Drugs 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 238000010298 pulverizing process Methods 0.000 claims 2
- 238000011278 co-treatment Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000011575 calcium Substances 0.000 abstract description 95
- 229910052791 calcium Inorganic materials 0.000 abstract description 95
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 87
- 230000037182 bone density Effects 0.000 abstract description 8
- 210000000963 osteoblast Anatomy 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 17
- 210000000988 bone and bone Anatomy 0.000 description 15
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 14
- 244000046146 Pueraria lobata Species 0.000 description 14
- 235000010575 Pueraria lobata Nutrition 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- 244000241838 Lycium barbarum Species 0.000 description 12
- 235000015459 Lycium barbarum Nutrition 0.000 description 12
- 235000015468 Lycium chinense Nutrition 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 10
- 235000018927 edible plant Nutrition 0.000 description 9
- 239000006041 probiotic Substances 0.000 description 9
- 235000018291 probiotics Nutrition 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000037831 Polygonatum sibiricum Species 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 101710190440 Cytotoxin 1 Proteins 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 230000003262 anti-osteoporosis Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000020247 cow milk Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000668 effect on calcium Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001863 plant nutrition Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
Abstract
本发明公开一种预防老年骨质疏松的营养包制剂及其应用,属于医药技术领域。为了提供一种预防老年骨质疏松的营养包制剂,本发明提供一种预防老年骨质疏松的营养包制剂,所述营养包制剂由以下重量份数组成:脱脂乳粉20‑30份、乳清蛋白粉10‑20份、乳矿物盐1‑2份、初乳碱性蛋白0.1‑0.3份、枸杞1‑3份、黄精1‑3份、葛根1‑3份、植物乳杆菌菌粉2‑5份、营养强化剂1‑3份和复合维生素0.08‑0.12份。能够满足一般骨质疏松人群补钙需求,还能够提高骨密度,促进成骨细胞增殖分化,进一步提高钙生物利用率,有效防治骨质疏松症。
Description
技术领域
本发明属于生物医药技术领域,具体涉及一种预防老年骨质疏松的营养包制剂及其应用。
背景技术
骨质疏松症是一种常见的进行性的全身骨骼疾病,病因非常复杂,其与衰老、内分泌紊乱、钙吸收不良以及免疫、营养和遗传因素密切相关。其特征是骨量低、骨组织微结构退化,骨脆化导致骨折风险升高,从而引起致残率、致死率风险升高,尤其是对老年人和绝经后妇女影响最大。目前大多数药物如选择性雌激素受体调节剂如雷洛昔芬、降钙素、双磷酸盐类以及c-Src激酶抑制剂如赛拉替尼等都可减少骨的丢失,但不能恢复丢失的骨密度和骨强度,且有一定程度的副作用。药食同源植物含有大量活性物质,可以通过调节骨特异性基质蛋白、转录因子、信号通路、靶点等环节发挥抗骨质疏松症作用,通过自身特性治疗骨质疏松症,可以最大程度的减少副作用的产生。
发明内容
本发明的目的是为了提供一种预防老年骨质疏松的营养包制剂。与现有的抗骨质疏松产品相比,针对人群种类范围更广,效果显著,安全稳定,适合长期使用。
本发明提供一种预防老年骨质疏松的营养包制剂,所述营养包制剂由以下重量份数组成:脱脂乳粉20-30份、乳清蛋白粉10-20份、乳矿物盐1-2份、初乳碱性蛋白0.1-0.3份、枸杞1-3份、黄精1-3份、葛根1-3份、植物乳杆菌菌粉2-5份、营养强化剂1-3份和复合维生素0.08-0.12份。
进一步地限定,所述营养包制剂由以下重量份数组成:脱脂乳粉20份、乳清蛋白粉10份、乳矿物盐1份、初乳碱性蛋白0.1份、枸杞1份、黄精1份、葛根1份、植物乳杆菌菌粉2份、营养强化剂1份和复合维生素0.08份。
进一步地限定,所述营养包制剂由以下重量份数组成:脱脂乳粉30份、乳清蛋白粉20份、乳矿物盐2份、初乳碱性蛋白0.3份、枸杞3份、黄精3份、葛根3份、植物乳杆菌菌粉5份、营养强化剂3份和复合维生素0.12份。
进一步地限定,所述营养包制剂由以下重量份数组成:脱脂乳粉22份、乳清蛋白粉18份、乳矿物盐2份、初乳碱性蛋白0.15份、枸杞3份、黄精2份、葛根1份、植物乳杆菌菌粉2份、营养强化剂2份和复合维生素0.1份。
进一步地限定,所述复合维生素的成分是维生素A25份,维生素D5份,维生素E60份,维生素C10份。
进一步地限定,所述营养强化剂包括硫酸亚铁10份,硫酸锌40份,柠檬酸锌20份,碘化钾10份、磷酸镁20份。
本发明提供上述的营养包制剂的制备方法,所述制备方法如下:将每个成分分别进行粉碎、调浆剪切、均质和灭处理。经过充分混合之后,采用喷雾干燥技术获得营养包制剂。
进一步地限定,所述粉碎的条件是使用粉碎机进行粉碎后过40目筛,使筛过的枸杞、黄精和葛根粉末大小均一;所述的菌粉喷雾干燥的条件是进风温度160℃、排风温度80℃,进样量100mL/h;所述调浆剪切的条件是80℃纯净水在调浆罐中进行调浆,剪切15min;所述均质的条件是均质压力15MPa-20MPa;所述灭菌的条件是巴氏杀菌;所述喷雾干燥的条件是进风温度160-180℃,排风温度60-80℃,泵压力150-250bar,负压-4.5至-3.5mba。
本发明提供上述的营养包制剂在制备预防/治疗或辅助治疗骨质疏松的药物中的应用。
进一步地限定,所述药物的剂型为片剂、胶囊剂、颗粒剂、散剂、液体制剂中的任意一种。
有益效果:第一组负责提供充足钙源和营养:主要包括脱脂乳粉25份,乳清蛋白粉18份、乳矿物盐2份、初乳碱性蛋白0.15份、营养强化剂1-3份等。第一组有效成分作为主要钙源除了提供充足钙,还能够提供主要营养成分、蛋白质、矿物质和糖分。
第二组为促进肠道钙吸收:主要包括植物乳杆菌2份和复合维生素0.1份。
植物乳杆菌JJBYG12的作用是调节肠道菌群环境和提高钙富集量。植物乳杆菌在肠道中的数量的增加,提高肠道的消化能力和钙吸收能力,为促进钙吸收提供途径。植物乳杆菌JJBYG12可以将牛乳中的无机钙转化为有机钙,并且富集在自身菌体周围,提高了钙富集量,提高身体对钙的吸收。另外,牛乳本身含有大量磷脂和钙,在此基础上补充维生素D可以更好的促进钙吸收。
第三组负责调节细胞活性、改善机体信号通路,主要成分为枸杞粉3份,黄精粉2份,葛根粉1份。研究表明,药食同源植物含有多种活性物质,枸杞、黄精、葛根作为药食同源植物,具有抗骨质疏松作用。枸杞可以抑制破骨细胞活性,降低骨转化率,加强骨形成;黄精主要通过蛋白的积累表达和信号调控来实现;葛根不仅可以通过抑制炎症反应改善骨质疏松,还通过调节肠道微生物释放的可溶性细胞因子和修复肠黏膜完整性,改善骨微环境。三者进行组合,起到调节细胞活性、改善机体通路的共同作用。与现有技术相比,本发明的有益效果是合理搭配维生素、矿物质、初乳碱性蛋白等成分,还增加了益生菌和药食同源植物,起到的效果并不是单个物质的叠加,而是协同的作用。植物乳杆菌JJBYG12和药食同源植物的添加从富集钙、调节钙吸收途径、调节肠道菌群平衡、益生菌增殖等多方面提高了营养包制剂的补钙性能,从而更加有效的降低了因钙摄入不足或钙利用率下降导致骨质疏松症发生的几率。
附图说明
图1为药食同源植物益生菌营养包制剂对小鼠骨骼微观结构和生长状态的影响;
具体实施方式
植物乳杆菌JJBYG12(记载在此文章Preparation of synbiotic milk powderand its effect on calcium absorption and the bone microstructure in calciumdeficient mice)。
实施例1.制备营养包制剂
1.营养包制剂成分:脱脂乳粉20份、乳清蛋白粉10份、乳矿物盐1份、初乳碱性蛋白0.1份、枸杞1份、黄精1份、葛根1份、植物乳杆菌菌粉2份、营养强化剂1份和复合维生素0.08份。
营养强化剂:每份营养强化剂含有硫酸亚铁0.1g,硫酸锌0.4g,柠檬酸锌0.2g,碘化钾0.1g、磷酸镁0.2g。
复合维生素:每份复合维生素含有维生素A2500μg,维生素D50μg,维生素E6000μg,维生素C300μg。
2.制备方法:步骤1,采用进风温度160℃、排风温度80℃,进样量100mL/h的条件,对植物乳杆菌JJBYG12进行喷雾干燥,制得菌粉。
步骤2,分别按重量份数将脱脂乳粉20份、乳清蛋白粉10份加入调浆罐中,加入10倍重量80℃的纯净水并搅拌均匀,充分溶解。依次向调浆罐中加入乳矿物盐1份、初乳碱性蛋白0.1份、枸杞1份、黄精1份、葛根1份、植物乳杆菌菌粉2份、营养强化剂1份和复合维生素0.08份,进行充分搅拌溶解。将物料整体加入到剪切罐中,剪切15min,配制完成。
步骤3,采用高压均质机将配制完成的物料进行均质,均质压力为20MPa。
步骤4,对均质完成的物料进行巴氏杀菌,冷却至室温后进行浓缩。
步骤5,浓缩后的物料进行喷雾干燥,条件为进风温度180℃,排风温度80℃,泵压力200bar,负压-4mba。
实施例2.制备营养包制剂
1.营养包制剂成分:脱脂乳粉30份、乳清蛋白粉20份、乳矿物盐2份、初乳碱性蛋白0.3份、枸杞3份、黄精3份、葛根3份、植物乳杆菌菌粉5份、营养强化剂3份和复合维生素0.12份。
营养强化剂:每份营养强化剂含有硫酸亚铁0.1g,硫酸锌0.4g,柠檬酸锌0.2g,碘化钾0.1g、磷酸镁0.2g。
复合维生素:每份复合维生素含有维生素A2500μg,维生素D50μg,维生素E6000μg,维生素C300μg。
3.制备方法:步骤1,采用进风温度160℃、排风温度80℃,进样量100mL/h的条件,对植物乳杆菌JJBYG12进行喷雾干燥,制得菌粉。
步骤2,分别按重量份数将脱脂乳粉20份、乳清蛋白粉10份加入调浆罐中,加入10倍重量80℃的纯净水并搅拌均匀,充分溶解。依次向调浆罐中加入乳矿物盐1份、初乳碱性蛋白0.1份、枸杞1份、黄精1份、葛根1份、植物乳杆菌菌粉2份、营养强化剂1份和复合维生素0.08份,进行充分搅拌溶解。将物料整体加入到剪切罐中,剪切15min,配制完成。
步骤3,采用高压均质机将配制完成的物料进行均质,均质压力为20MPa。
步骤4,对均质完成的物料进行巴氏杀菌,冷却至室温后进行浓缩。
步骤5,浓缩后的物料进行喷雾干燥,条件为进风温度180℃,排风温度80℃,泵压力200bar,负压-4mba。
实施例3.制备营养包制剂
1.营养包制剂成分:脱脂乳粉22份、乳清蛋白粉18份、乳矿物盐2份、初乳碱性蛋白0.15份、枸杞3份、黄精2份、葛根1份、植物乳杆菌菌粉2份、营养强化剂2份和复合维生素0.1份。
营养强化剂:每份营养强化剂含有硫酸亚铁0.1g,硫酸锌0.4g,柠檬酸锌0.2g,碘化钾0.1g、磷酸镁0.2g。
复合维生素:每份复合维生素含有维生素A2500μg,维生素D50μg,维生素E6000μg,维生素C300μg。
2.制备方法:步骤1,采用进风温度160℃、排风温度80℃,进样量100mL/h的条件,对植物乳杆菌JJBYG12进行喷雾干燥,制得菌粉。
步骤2,分别按重量份数将脱脂乳粉20份、乳清蛋白粉10份加入调浆罐中,加入10倍重量80℃的纯净水并搅拌均匀,充分溶解。依次向调浆罐中加入乳矿物盐1份、初乳碱性蛋白0.1份、枸杞1份、黄精1份、葛根1份、植物乳杆菌菌粉2份、营养强化剂1份和复合维生素0.08份,进行充分搅拌溶解。将物料整体加入到剪切罐中,剪切15min,配制完成。
步骤3,采用高压均质机将配制完成的物料进行均质,均质压力为20MPa。
步骤4,对均质完成的物料进行巴氏杀菌,冷却至室温后进行浓缩。
步骤5,浓缩后的物料进行喷雾干燥,条件为进风温度180℃,排风温度80℃,泵压力200bar,负压-4mba。
实施例4.营养包制剂的应用
试验例1:下面的动物试验描述了本发明对小鼠体重、体长和食物利用率的影响。
组1:空白组:喂食基础饲料。
组2:低钙组:喂食低钙饲料。
组3:阳性对照组:喂食低钙饲料并灌胃碳酸钙。
组4:实施例1:喂食低钙饲料并实施例1。
组5:实施例2:喂食低钙饲料并实施例2。
组6:枸杞组:喂食低钙饲料并灌胃只添加枸杞的实施例3(不含黄精和葛根)。
组7:黄精组:喂食低钙饲料并灌胃只添加黄精的实施例3(不含枸杞和葛根)。
组8:葛根组:喂食低钙饲料并灌胃只添加葛根的实施例3(不含枸杞和黄精)。
组9:实施例3:喂食低钙饲料并灌胃实施例3。
低钙饲料含钙量为每克饲料1.39mg钙,基础饲料含钙量为每克饲料18.3mg钙。灌胃碳酸钙的钙量与营养包制剂钙量相等,按照小鼠体重决定灌胃剂量。每组的一份营养包制剂为10g,每只小鼠灌胃剂量为0.01份/10g·bw(例如10g小鼠吃0.1g的营养包)。
检测指标:第四周和第八周结束前检测小鼠体重和体长,在检测前12h禁食不禁水,使用游标卡尺测定小鼠体长,使用电子秤测定小鼠体重。每天记录小鼠进食量,第八周结束后计算食物利用率。
表1药食同源植物益生菌营养包制剂对小鼠体重、体长和食物利用率的影响(n=10)
上述数值以平均数±标准差(n=10/组)表示,表中同列不同字母表示差异显著(p<0.05)
表1结果显示,组9的体长显著大于组2(p<0.05),组9的体长显著高于组6、组7和组8,说明黄精、枸杞和葛根的单一效果差于组合效果。组3相较于组2体长没有显著差异,各组之间体重没有显著差异(p>0.05)。表明本营养包制剂可以促进小鼠骨骼生长发育,但不会使小鼠体重过大。
试验例2:下面的动物试验描述了本发明对提高钙表观吸收率和保留率的有益影响。
组1:空白组:喂食基础饲料。
组2:低钙组:喂食低钙饲料。
组3:阳性对照组:喂食低钙饲料并灌胃碳酸钙。
组4:实施例1:喂食低钙饲料并实施例1。
组5:实施例2:喂食低钙饲料并实施例2。
组6:枸杞组:喂食低钙饲料并灌胃只添加枸杞的实施例3(不含黄精和葛根)。
组7:黄精组:喂食低钙饲料并灌胃只添加黄精的实施例3(不含枸杞和葛根)。
组8:葛根组:喂食低钙饲料并灌胃只添加葛根的实施例3(不含枸杞和黄精)。
组9:实施例3:喂食低钙饲料并灌胃实施例3。
检测指标:试验在第25天开始收集小鼠粪便和尿液,连续收集72h,计算小鼠的钙表观吸收率和钙保留率。计算公式如下:
试验结果:对试验的结果进行计算分析,结果见表2。
表2药食同源植物益生菌营养包制剂对小鼠钙表观吸收率和钙保留率的影响(n=10)
上述数值以平均数±标准差(n=10/组)表示,表中同列不同字母表示差异显著(p<0.05)
从试验结果来看,组9相较于其余各组,钙表观吸收率和钙保留率均有显著差异,证明植物乳杆菌JJBYG12对乳粉中的钙进行了富集,枸杞、黄精、葛根通过对机体蛋白和信号通路的调节,提高了对钙的吸收。表明食用本营养包制剂可以明显增加机体钙的吸收和保留。
试验例3:下面的动物试验描述了本发明对提高股骨理化性质和骨钙的有益影响。
组1:空白组:喂食基础饲料。
组2:低钙组:喂食低钙饲料。
组3:阳性对照组:喂食低钙饲料并灌胃碳酸钙。
组4:实施例1:喂食低钙饲料并实施例1。
组5:实施例2:喂食低钙饲料并实施例2。
组6:枸杞组:喂食低钙饲料并灌胃只添加枸杞的实施例3(不含黄精和葛根)。
组7:黄精组:喂食低钙饲料并灌胃只添加黄精的实施例3(不含枸杞和葛根)。
组8:葛根组:喂食低钙饲料并灌胃只添加葛根的实施例3(不含枸杞和黄精)。
组9:实施例3:喂食低钙饲料并灌胃实施例3。
表3药食同源植物益生菌营养包制剂对小鼠股骨的影响
上述数值以平均数±标准差(n=10/组)表示,表中同列不同字母表示差异显著(p<0.05)。
从试验结果来看,在喂食低钙饲料的基础上,每天灌胃本营养包制剂可以显著提高小鼠的股骨长度、股骨直径、股骨重量和骨钙含量(p<0.05)。单一植物营养包制剂效果与使用益生菌效果相差不明显(p>0.05)。
试验例4:下面的动物试验描述了本发明对血清钙、血清磷和骨形成骨吸收的影响。
组1:空白组:喂食基础饲料。
组2:低钙组:喂食低钙饲料。
组3:阳性对照组:喂食低钙饲料并灌胃碳酸钙。
组4:实施例1:喂食低钙饲料并实施例1。
组5:实施例2:喂食低钙饲料并实施例2。
组6:枸杞组:喂食低钙饲料并灌胃只添加枸杞的实施例3(不含黄精和葛根)。
组7:黄精组:喂食低钙饲料并灌胃只添加黄精的实施例3(不含枸杞和葛根)。
组8:葛根组:喂食低钙饲料并灌胃只添加葛根的实施例3(不含枸杞和黄精)。
组9:实施例3:喂食低钙饲料并灌胃实施例3。
检测指标:试验在第28天结束,眼球取血,3000rpm离心15min,收集上层血清,采用血清钙、血清磷、碱性磷酸酶(ALP)和1型胶原末端肽(CTX-1)试剂盒对相关指标进行检测。
试验结果:对试验的结果进行分析,结果见表3。
表4药食同源植物益生菌营养包制剂对小鼠钙血清钙、血清磷、ALP、CTX-1的影响(n=10)
上述数值以平均数±标准差(n=10/组)表示,表中同列不同字母表示差异显著(p<0.05)。
血清钙碱性磷酸酶(ALP)和I型胶原C末端肽(CTX-1)作为两种十分重要的骨形成标志物和骨吸收标志物,能很好地反映成骨细胞和破骨细胞的功能和活性。从试验结果来看,组9的ALP和CTX-1均显著降低(p<0.05),说明食用本营养包制剂可以改善成骨细胞功能和抑制体内破骨细胞生成,并且提高体内血清钙、血清磷含量。
试验例5:下面的动物试验描述了本发明对小鼠股骨骨密度、骨小梁数目和骨小梁厚度的影响。
组1:空白组:喂食基础饲料。
组2:低钙组:喂食低钙饲料。
组3:阳性对照组:喂食低钙饲料并灌胃碳酸钙。
组4:实施例1:喂食低钙饲料并实施例1。
组5:实施例2:喂食低钙饲料并实施例2。
组6:枸杞组:喂食低钙饲料并灌胃只添加枸杞的实施例3(不含黄精和葛根)。
组7:黄精组:喂食低钙饲料并灌胃只添加黄精的实施例3(不含枸杞和葛根)。
组8:葛根组:喂食低钙饲料并灌胃只添加葛根的实施例3(不含枸杞和黄精)。
组9:实施例3:喂食低钙饲料并灌胃实施例3。
检测指标:试验在第28天结束,眼球取血后,处死并解剖小鼠。取小鼠左侧股骨,进行骨密度、骨小梁数目和厚度的检测。
表5药食同源植物益生菌营养包制剂对小鼠股骨骨密度、骨小梁数目和骨小梁厚度的影响(n=10)
上述数值以平均数±标准差(n=10/组)表示,表中同列不同字母表示差异显著(p<0.05)。
从试验结果来看,食用本营养包制剂可以改善股骨骨密度,并可以增加小鼠骨小梁数目和厚度。骨密度是最直观反映骨骼强度的一个重要指标,而骨小梁数目的增加是提高骨密度的直接原因。表5的结果说明长期食用本营养包制剂可以强化骨骼。
试验例6:下面的动物试验描述了本发明对小鼠骨骼微观结构和生长状态的影响。
组1:空白组:喂食基础饲料。
组2:低钙组:喂食低钙饲料。
组3:阳性对照组:喂食低钙饲料并灌胃碳酸钙。
组4:实施例1:喂食低钙饲料并实施例1。
组5:实施例2:喂食低钙饲料并实施例2。
组6:枸杞组:喂食低钙饲料并灌胃只添加枸杞的实施例3(不含黄精和葛根)。
组7:黄精组:喂食低钙饲料并灌胃只添加黄精的实施例3(不含枸杞和葛根)。
组8:葛根组:喂食低钙饲料并灌胃只添加葛根的实施例3(不含枸杞和黄精)。
组9:实施例3:喂食低钙饲料并灌胃实施例3。
检测指标:试验在第28天结束,处死并解剖小鼠。取小鼠右侧股骨,进行切片并进行苏木精伊红染色,通过Moticam显微摄影成像系统观察切片。
从图1试验结果来看,组2细胞排列疏松,胞质淡染且不均匀,胞核固缩,成骨细胞减少。组6、组7、组8和组9细胞排列较为规整,成骨细胞增多。图1结果说明长期食用本营养包制剂可以提高成骨细胞数目,有助于骨骼恢复为健康骨组织。
Claims (10)
1.一种预防老年骨质疏松的营养包制剂,其特征在于,所述营养包制剂由以下重量份数组成:脱脂乳粉20-30份、乳清蛋白粉10-20份、乳矿物盐1-2份、初乳碱性蛋白0.1-0.3份、枸杞1-3份、黄精1-3份、葛根1-3份、植物乳杆菌菌粉2-5份、营养强化剂1-3份和复合维生素0.08-0.12份。
2.根据权利要求1所述的营养包制剂,其特征在于,所述营养包制剂由以下重量份数组成:脱脂乳粉20份、乳清蛋白粉10份、乳矿物盐1份、初乳碱性蛋白0.1份、枸杞1份、黄精1份、葛根1份、植物乳杆菌菌粉2份、营养强化剂1份和复合维生素0.08份。
3.根据权利要求1所述的营养包制剂,其特征在于,所述营养包制剂由以下重量份数组成:脱脂乳粉30份、乳清蛋白粉20份、乳矿物盐2份、初乳碱性蛋白0.3份、枸杞3份、黄精3份、葛根3份、植物乳杆菌菌粉5份、营养强化剂3份和复合维生素0.12份。
4.根据权利要求1所述的营养包制剂,其特征在于,所述营养包制剂由以下重量份数组成:脱脂乳粉22份、乳清蛋白粉18份、乳矿物盐2份、初乳碱性蛋白0.15份、枸杞3份、黄精2份、葛根1份、植物乳杆菌菌粉2份、营养强化剂2份和复合维生素0.1份。
5.根据权利要求1所述的营养包制剂,其特征在于,所述复合维生素的成分是维生素A25份,维生素D5份,维生素E60份,维生素C10份。
6.根据权利要求1所述的营养包制剂,其特征在于,所述营养强化剂包括硫酸亚铁10份,硫酸锌40份,柠檬酸锌20份,碘化钾10份、磷酸镁20份。
7.权利要求1-6任一项所述的营养包制剂的制备方法,其特征在于,所述制备方法如下:将每个成分分别进行粉碎、调浆剪切、均质和灭处理。经过充分混合之后,采用喷雾干燥技术获得营养包制剂。
8.根据权利要求7所述的制备方法,其特征在于,其特征在于,所述粉碎的条件是使用粉碎机进行粉碎后过40目筛,使筛过的枸杞、黄精和葛根粉末大小均一;所述的菌粉喷雾干燥的条件是进风温度160℃、排风温度80℃,进样量100mL/h;所述调浆剪切的条件是80℃纯净水在调浆罐中进行调浆,剪切15min;所述均质的条件是均质压力15MPa-20MPa;所述灭菌的条件是巴氏杀菌;所述喷雾干燥的条件是进风温度160-180℃,排风温度60-80℃,泵压力150-250bar,负压-4.5至-3.5mba。
9.权利要求1-6任一项所述的营养包制剂在制备预防/治疗或辅助治疗骨质疏松的药物中的应用。
10.根据权利要求9所述的应用,其特征在于,所述药物的剂型为片剂、胶囊剂、颗粒剂、散剂、液体制剂中的任意一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310596136.2A CN116585455A (zh) | 2023-05-24 | 2023-05-24 | 一种预防老年骨质疏松的营养包制剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310596136.2A CN116585455A (zh) | 2023-05-24 | 2023-05-24 | 一种预防老年骨质疏松的营养包制剂及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116585455A true CN116585455A (zh) | 2023-08-15 |
Family
ID=87605995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310596136.2A Pending CN116585455A (zh) | 2023-05-24 | 2023-05-24 | 一种预防老年骨质疏松的营养包制剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116585455A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118749660A (zh) * | 2024-09-05 | 2024-10-11 | 四平君乐宝乳业有限公司 | 促进骨骼健康的组合物及其应用 |
-
2023
- 2023-05-24 CN CN202310596136.2A patent/CN116585455A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118749660A (zh) * | 2024-09-05 | 2024-10-11 | 四平君乐宝乳业有限公司 | 促进骨骼健康的组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4447661B2 (ja) | 増加した骨吸収の治療のための植物抽出物 | |
CA3014897C (en) | Nutritional support for animals via administration of an algal derived supplement | |
US20050106215A1 (en) | Food or pet food composition containing plant extract for bone health | |
CN101496576B (zh) | 一种供骨伤患者食用含短肽的特殊膳食用食品配方 | |
CN111264632A (zh) | 一种助钙长高的儿童配方奶粉及其制备方法 | |
CN116585455A (zh) | 一种预防老年骨质疏松的营养包制剂及其应用 | |
CN110720516A (zh) | 骨营养特膳食品及其制备方法和应用 | |
CN116172191B (zh) | 营养组合物及其在制备抗炎产品中的应用 | |
JP2006256968A (ja) | 骨代謝改善剤とその製造方法 | |
Lee et al. | An enhanced intestinal absorption of calcium in the rat directly attributed to dietary casein | |
KATO et al. | Milk basic protein enhances the bone strength in ovariectomized rats | |
CN108576816A (zh) | 一种增加骨密度的组合物 | |
CN101279089B (zh) | 阿胶钙组合物及其制备方法 | |
EP2908828B1 (en) | Galactagogue compositions based on phosphatidylserine | |
CN108420890B (zh) | 一种具有降血脂作用的组合物及其制备方法 | |
EP1622590A2 (en) | Novel composition for hormonal balance and uses thereof | |
CN113729230A (zh) | 预防骨质疏松或增强骨密度的组合物及其制备和应用 | |
WO2016206363A1 (zh) | 吉林人参低聚肽在制备抗氧化的食品或保健食品中的用途 | |
US9308241B2 (en) | Food supplement having high immunological value, based on a protein matrix | |
ES2393360T3 (es) | Un procedimiento de fabricación de una preparación de lectina, la preparación de lectina y procedimientos de administración de la preparación a mamiferos | |
CN118717952A (zh) | 一种增加骨密度的组合物及其应用 | |
LU506958B1 (en) | Bone-derived factor containing calcium B-hydroxy-B-methyl butyrate and preparation method thereof | |
CN1328964C (zh) | 一种微米糖参绿猴王西天斗蜂胶滋阴养胃奶粉制备方法 | |
KR20100056329A (ko) | 골다공증 예방 및 치료용 칼슘 화합물 및 칼슘 화합물 시비쌀 | |
CN116474076A (zh) | 用于肌少症防治的组合物及制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |